CEO Mark Tarr Sells $21.7M in Encompass Health Stock Near 52-Week High
EHC sits 35% above its 52-week low of $92.77.
Summary
Encompass Health CEO Mark Tarr sold $21.7M in stock near the 52-week high, reducing his direct stake by 39% shortly after strong Q2 earnings and a guidance raise.
Key Events · Ownership and Investor Activity · EHC
-
CEO Sells $21.7M in Open Market
Mark J. Tarr, President and CEO, sold 173,148 shares at $124.93–$126.22, generating $21.7M. Post-sale direct holdings: 269,393 shares.
-
Sale Near 52-Week High After Strong Q2
The sale occurred on August 10, 2026, with the stock at $125.55, near its $127.99 52-week high, following Q2 revenue of $1.6B (+9.6% YoY) and raised full-year guidance.
-
No 10b5-1 Plan; Discretionary Sale
The filing indicates the sale was not made under a pre-arranged 10b5-1 trading plan, suggesting a discretionary decision by the CEO.
-
Reduces Direct Stake by 39%
The transaction reduced Tarr's directly held shares from 442,541 to 269,393, a 39% decrease, though he retains significant equity exposure.
Analysis · EHC · Industrial Applications And Services
President and CEO Mark J. Tarr sold 173,148 shares for $21.7 million in open-market transactions on August 10, 2026, at prices between $124.93 and $126.22. The sale represents a significant reduction in his direct holdings—from 442,541 shares to 269,393—and comes just days after the company reported strong Q2 results and raised guidance, with the stock trading near its 52-week high. While the sale was not executed under a 10b5-1 plan, the timing and magnitude may raise questions about management's conviction, though the company's recent performance and debt refinancing activities provide a positive backdrop.
At the time of this filing, EHC was trading at $125.55 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $92.77 to $127.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.